QC
APRE icon

Quent Capital’s Aprea Therapeutics APRE Stock Holding History

Quent Capital’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3
Closed -$13 – 1324
2023
Q1 		$13 Sell
3
-1
-25% -$7 ﹤0.01% 1318
2022
Q4 		$25 Hold
4
– – ﹤0.01% 1305
2022
Q3 		$0 Hold
4
– – ﹤0.01% 1217
2022
Q2 		$0 Hold
4
– – ﹤0.01% 1167
2022
Q1 		$0 Buy
+4
New +$164 ﹤0.01% 1256

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Quent Capital's APRE Position: Q2 2023 in Review

Quent Capital sold out of Aprea Therapeutics (APRE) in Q2 2023, closing a stake of 3 shares — an estimated $13 sold.

Quent Capital first reported a position in APRE in Q1 2022 and held it in 5 quarters. The position peaked at $25 in Q4 2022. 19 funds tracked by Wall St. Rank hold APRE as of Q2 2023.

  • Quent Capital reported no remaining Aprea Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Quent Capital sold 3 Aprea Therapeutics shares in Q2 2023, an estimated $13.
  • Quent Capital first reported a position in Aprea Therapeutics in Q1 2022 and held it in 5 quarters.
  • Quent Capital's Aprea Therapeutics position peaked at $25 in Q4 2022.
  • 19 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2023.

Based on Quent Capital's 13F filing for Q2 2023, filed 10 Jul 2023.